share_log

B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6

Benzinga ·  Jun 27 13:28

B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $9 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment